Hansoh Pharma, a generic/novel drug company headquartered in Lianyungang, Jiangsu province, has set the pricing range in an upcoming Hong Kong IPO slated to raise up to $1 billion at a $10 billion valuation. Hansoh has signed up nine cornerstone investors who will purchase $344 million of the IPO. A profitable company, Hansoh reported $1.1 billion in 2018 revenues and more than $280 million in profits, a 19% increase from the year earlier. At a $10 billion market cap, Hansoh would be priced at 36 times trailing earnings. More details....
Share this with colleagues:
Original Article: Hansoh Seeks to Raise $1 Billion at Top of Hong Kong IPO Range